Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The inhibitor of DNA binding 2, dominant negative helix-loop-helix protein,
ID2
, acts as an oncogene and elevated levels of
ID2
have been reported in several malignancies. Whereas some inducers of the
ID2
gene have been characterized, little is known regarding the proteins capable to repress its expression. We developed siRNA microarrays to perform a large scale loss-of-function screen in human adult keratinocytes engineered to express GFP under the control of the upstream region of
ID2
gene. We screened the effect of siRNA-dependent inhibition of 220
cancer-associated
genes on the expression of the
ID2
::GFP reporter construct. Three genes NBN, RAD21, and p63 lead to a repression of
ID2
promoter activity. Strikingly NBN and RAD21 are playing on major role in cell cycle progression and mitosis arrest. These results underline the pregnant need to silence
ID2
expression at transcript level to promote cell cycle exit. Central to this inhibitory mechanism we find p63, a key transcription factor in epithelial development and differentiation, which binds specific cis-acting sequence within the
ID2
gene promoter both in vitro and in vivo. P63 would not suppress
ID2
expression, but would rather prevent excessive expression of that protein to enable the onset of keratinocyte differentiation.
...
PMID:Large scale RNAi screen reveals that the inhibitor of DNA binding 2 (ID2) protein is repressed by p53 family member p63 and functions in human keratinocyte differentiation. 2147 50